Press release
Cutaneous Lupus Erythematosus Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Cutaneous Lupus Erythematosus Treatment Landscape. Click here to read more @ Cutaneous Lupus Erythematosus Pipeline Outlook [https://www.delveinsight.com/sample-request/cutaneous-lupus-erythematosus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Cutaneous Lupus Erythematosus Pipeline Report
* In April 2025, AstraZeneca announced a study are to evaluate the efficacy of anifrolumab compared with placebo in reducing skin disease in participants with active chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The secondary objectives of the study are to evaluate additional efficacy parameters of anifrolumab, safety, tolerability, quality of life, pharmacokinetics, pharmacodynamics, and immunogenicity.
* In April 2025, Biogen conducted a study is to learn about the effect litifilimab has on lowering the activity of the skin disease. Researchers will measure symptoms of CLE over time using a variety of scoring tools. These include the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI), the Cutaneous Lupus Activity of Investigator's Global Assessment-Revised (CLA-IGA-R), and the SELENA-SLEDAI Flare Index (SFI).
* In April 2025, Pfizer organized a study is to learn about the effects, safety and how PF-06823859 is processed in adults with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) showing some skin symptoms.
* DelveInsight's Cutaneous Lupus Erythematosus pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Cutaneous Lupus Erythematosus treatment.
* The leading Cutaneous Lupus Erythematosus Companies such as Hoth Therapeutics, Zylo Therapeutics, Sanofi, Gilead Sciences, Bristol-Myers Squibb, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, and Horizon Therapeutics and others.
* Promising Cutaneous Lupus Erythematosus Pipeline Therapies such as Litifilimab, Daxdilimab, SOTYKTU (deucravacitinib), Edecesertib, DS-7011a, Enpatoran, and others.
Discover groundbreaking developments in Cutaneous Lupus Erythematosus therapies! Gain in-depth knowledge of key Cutaneous Lupus Erythematosus clinical trials, emerging drugs, and market opportunities @ Cutaneous Lupus Erythematosus Clinical Trials Assessment [https://www.delveinsight.com/sample-request/cutaneous-lupus-erythematosus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Cutaneous Lupus Erythematosus Emerging Drugs Profile
* BIIB059: Biogen
Litifilimab (known as BIIB059), discovered and developed in-house by Biogen scientists, is a humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) and is being investigated for the potential treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Currently it is being evaluated in Phase II clinical trial in Participants with Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy.
* SAR443122: Sanofi
SAR443122 is a peripherally-restricted small molecule inhibitor of RIPK1 being evaluated in patients with cutaneous lupus erythematosus (CLE). Denali and Sanofi entered into a broad collaboration in October 2018 for the global development and commercialization of RIPK1 inhibitors. This includes peripherally restricted molecules such as SAR443122 (DNL758) and CNS-penetrant molecules such as DNL788 (SAR443820). A Phase II clinical study is assessing the efficacy and safety of the RIPK1-inhibitor SAR443122 in patients with moderate to severe subacute or discoid/chronic cutaneous lupus erythematosus.
The Cutaneous Lupus Erythematosus Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Cutaneous Lupus Erythematosus with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cutaneous Lupus Erythematosus Treatment.
* Cutaneous Lupus Erythematosus Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Cutaneous Lupus Erythematosus Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cutaneous Lupus Erythematosus market
Stay informed about the Cutaneous Lupus Erythematosus pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Cutaneous Lupus Erythematosus Unmet Needs [https://www.delveinsight.com/sample-request/cutaneous-lupus-erythematosus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Cutaneous Lupus Erythematosus Companies
Hoth Therapeutics, Zylo Therapeutics, Sanofi, Gilead Sciences, Bristol-Myers Squibb, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, and Horizon Therapeutics and others.
Cutaneous Lupus Erythematosus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical.
Cutaneous Lupus Erythematosus Products have been categorized under various Molecule types such as
* Gene therapies
* Small molecule
* Vaccines
* Polymers
* Peptides
* Monoclonal antibodies
Transform your understanding of the Cutaneous Lupus Erythematosus Pipeline! See the latest progress in drug development and clinical research @ Cutaneous Lupus Erythematosus Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/cutaneous-lupus-erythematosus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Cutaneous Lupus Erythematosus Pipeline Report
* Coverage- Global
* Cutaneous Lupus Erythematosus Companies- Hoth Therapeutics, Zylo Therapeutics, Sanofi, Gilead Sciences, Bristol-Myers Squibb, Merck KGaA, Kyowa Kirin Co., Ltd., Priothera Ltd., Centessa Pharmaceuticals, and Horizon Therapeutics and others.
* Cutaneous Lupus Erythematosus Pipeline Therapies- Litifilimab, Daxdilimab, SOTYKTU (deucravacitinib), Edecesertib, DS-7011a, Enpatoran, and others.
* Cutaneous Lupus Erythematosus Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Cutaneous Lupus Erythematosus Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Dermatology Research-Access the Full Cutaneous Lupus Erythematosus Pipeline Analysis Today! @ Cutaneous Lupus Erythematosus Drugs and Companies [https://www.delveinsight.com/sample-request/cutaneous-lupus-erythematosus-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Cutaneous Lupus Erythematosus: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Cutaneous Lupus Erythematosus - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Cutaneous Lupus Erythematosus Collaboration Deals
* Late Stage Products (Phase III)
* Drug Name: Company Name
* Mid Stage Products (Phase II)
* SAR443122: Sanofi
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* VIB7734: Horizon Therapeutics
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* HT-005 Z-Pods: Hoth Therapeutics/Zylo Therapeutics
* Inactive Products
* Cutaneous Lupus Erythematosus Key Companies
* Cutaneous Lupus Erythematosus Key Products
* Cutaneous Lupus Erythematosus- Unmet Needs
* Cutaneous Lupus Erythematosus- Market Drivers and Barriers
* Cutaneous Lupus Erythematosus- Future Perspectives and Conclusion
* Cutaneous Lupus Erythematosus Analyst Views
* Cutaneous Lupus Erythematosus Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cutaneous-lupus-erythematosus-clinical-trials-and-studies-2025-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cutaneous Lupus Erythematosus Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here
News-ID: 4000126 • Views: …
More Releases from ABNewswire
Daily Vibe Launches Comprehensive Fitness Products Store for Diverse Consumer Ma …
New fitness retailer Daily Vibe enters the market with targeted product selections designed to support active lifestyles across multiple demographics. The startup focuses on serving fitness enthusiasts, health-conscious consumers, and older adults seeking quality fitness products.
Founded by Ja'von L. Watson and Joyleena S. Watson, AGAIT International is a fast-growing Atlanta-based tech company dedicated to solving social and economic challenges through creative business and digital solutions. The company develops and manages…
Prolift Handling Brings Advanced pewag Lifting Technology to Ireland
Prolift Handling launches pewag levo Balancer and levo Compensator in Ireland - two advanced lifting solutions that improve safety and precision in heavy lifting operations through remote-controlled positioning and automatic load balancing.
Dublin, Ireland - Sep 30, 2025 - Prolift Handling, Ireland's exclusive pewag partner, today launched two advanced lifting solutions designed to tackle the industry's most challenging safety and precision requirements: the pewag levo Balancer and pewag levo Compensator.
The pewag…
A Gem of Joy ABA Breaks Barriers to Access with In-Home Therapy Services for Fam …
A Gem of Joy ABA offers in-home therapy services for Maryland families, breaking barriers to access and providing personalized support for children's development.
Maryland - A Gem of Joy ABA, a leading provider of autism therapy solutions, is making a transformative impact on families across Maryland by offering flexible and personalized in-home ABA Therapy. This innovative approach aims to break down barriers to care by delivering services directly to families' homes,…
Ontario Therapy Takes Action to Break Mental Health Stigma with DBT Therapy in B …
Ontario Therapy is expanding access to DBT therapy in Bradford, helping individuals overcome mental health challenges with effective, stigma-free support and coping strategies.
Bradford, ON - Ontario Therapy is taking significant steps to combat the stigma surrounding mental health by expanding access to Dialectical Behavior Therapy (DBT) in Bradford. With a mission to create more inclusive and supportive mental health care environments, Ontario Therapy is offering DBT therapy to help individuals…
More Releases for Cutaneous
Cutaneous Lupus Erythematosus (CLE) Market
Introduction
Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin disorder, often associated with systemic lupus erythematosus (SLE), that presents as inflammation, rashes, and photosensitivity. While CLE is rarely fatal, it significantly affects patients' physical and emotional well-being, often leading to scarring, disfigurement, and social stigma.
Over the past decade, the market for CLE therapies has gained global importance as research into autoimmunity has accelerated and biologic therapies have transformed dermatology. Rising…
Cutaneous Angiosarcoma Market New Product Development & Latest Trends
Introduction
Cutaneous angiosarcoma is a rare and aggressive malignancy that originates from endothelial cells lining blood vessels and lymphatics in the skin. Though it represents a small fraction of soft-tissue sarcomas, its high recurrence rates, metastatic potential, and poor prognosis make it one of the most challenging cancers to manage. The condition most frequently affects elderly patients and is often associated with chronic lymphedema, prior radiation exposure, or immunosuppression.
Traditional management has…
Emerging Trends Influencing The Growth Of The Cutaneous T-Cell Lymphoma Market: …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Cutaneous T-Cell Lymphoma Market Size Expected to Be by 2034?
The market for cutaneous T-cell lymphoma has witnessed substantial growth in the past few years. It is projected to rise from a size of $2.54 billion in 2024 to $2.72 billion in 2025, equating to a compound annual…
Prominent Cutaneous Lupus Erythematosus Market Trend for 2025: Advancements In C …
What combination of drivers is leading to accelerated growth in the cutaneous lupus erythematosus market?
The rising prevalence of skin infections is expected to drive the growth of the cutaneous lupus erythematosus (CLE) market. Skin infections are caused by microorganisms that invade the skin, triggering immune responses that can worsen symptoms in individuals with CLE. For example, the UK saw a 33.7% increase in MRSA cases caused by skin and soft…
Key Trend Reshaping the Cutaneous Lupus Erythematosus Market in 2025: Advancemen …
What Are the Projections for the Size and Growth Rate of the Cutaneous Lupus Erythematosus Market?
The market size for cutaneous lupus erythematosus has seen quick expansion in the past few years. The growth is estimated to move from $2.24 billion in 2024 to $2.51 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 12.0%. This considerable increase in the historic period is a result of factors such as…
Cutaneous Lupus Erythematosus Market Trends & Analysis Report 2024
"The Business Research Company recently released a comprehensive report on the Global Cutaneous Lupus Erythematosus Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive…
